Comparative Pharmacology
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus MEPROBAMATE AND ASPIRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLURBIPROFEN SODIUM versus MEPROBAMATE AND ASPIRIN.
FLURBIPROFEN SODIUM vs MEPROBAMATE AND ASPIRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, thereby decreasing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Meprobamate is a carbamate derivative that acts as a CNS depressant, potentiating GABA-A receptor activity and inhibiting polysynaptic spinal reflexes. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
50 mg orally every 4 to 6 hours as needed; maximum 300 mg per day.
Aspirin 325 mg and meprobamate 200 mg orally every 6 to 8 hours as needed for pain or anxiety. Maximum daily dose: aspirin 3.9 g, meprobamate 1.6 g.
None Documented
None Documented
3-4 hours; in elderly or hepatic impairment may extend to 5-6 hours.
Aspirin: 15-20 minutes (parent drug), but salicylate half-life is dose-dependent: 2-3 hours for low doses, 15-30 hours for high doses. Meprobamate: 6-17 hours (mean 10 hours), prolonged in overdose or hepatic impairment.
Renal: 70% as conjugates (glucuronide) and unchanged drug (<1%); biliary/fecal: minimal.
Aspirin: Renal excretion of salicylates (75% as salicyluric acid, 10% as salicylic acid, 10% as phenolic glucuronide, 5% as acyl glucuronide). Meprobamate: Renal excretion (10-20% unchanged, 80-90% as hydroxylated metabolites) and biliary excretion (<5%).
Category D/X
Category D/X
NSAID
NSAID / Antiplatelet